Table 1.
Baseline characteristics of 172 Chinese patients with chronic lymphocytic leukemia (n = 172)
| Parameter | Median (range) | Cases (%) |
|---|---|---|
| Gender (n = 172) | ||
| Male | 113 (65.70) | |
| Female | 59 (34.30) | |
| Age | 62 (35–93) | |
| ≥60 years | 108 (62.79) | |
| <60 years | 64 (37.21) | |
| Binet stage (n = 172) | ||
| A | 83 (48.26) | |
| B | 36 (20.93) | |
| C | 53 (30.81) | |
| CD38 (n = 169) | ||
| Positive | 50 (29.59) | |
| Negative | 119 (70.41) | |
| ZAP‐70 (n = 167) | ||
| Positive | 44 (26.35) | |
| Negative | 123 (73.65) | |
| IGHV (n = 153) | ||
| Unmutated (≤2% deviation from a germline) | 52 (33.98) | |
| Mutated (>2% deviation from a germline) | 101 (66.02) | |
| p53 Mutation status (n = 156) | ||
| Presence | 28 (17.95) | |
| Absence | 128 (82.05) | |
| Treatment (n = 172) | ||
| No | 91 (52.91) | |
| Yes | 81 (47.09) | |
| Treatment regime (n = 81) | ||
| Rituximab‐based regimes | 36 (44.44) | |
| Other regimes | 45 (55.56) | |
| Cytogenetics (n = 172) | ||
| del(17p13) or del(11q22.3) | 45 (26.16) | |
| del(13q24) as the sole abnormality | 9 (5.23) | |
| Other | 118 (68.60) | |
| CD20% (n = 172) | 97.82% (0–100) | |
| CD20 MFI (n = 172) | 731.45 (0–9071.90) | |
IGHV, variable region of immunoglobulin genes; MFI, mean fluorescence intensity; ZAP‐70, zeta‐associated protein‐70.